https://scholars.lib.ntu.edu.tw/handle/123456789/146387
標題: | Elevated Serum Decoy Receptor 3 with Enhanced T Cell Activation in Systemic Lupus Erythematosus | 作者: | LEE, CHAU-SHOUN HU, CHUNG-YI TSAI, HWEI -FANG WU, CHIEN-SHENG HSIEH, SHIE-LIANG LIU, LI-CHUN HSU, PING-NING |
關鍵字: | apoptosis;DcR3;SLE;T cell activation | 公開日期: | 2008 | 卷: | v.151 | 期: | n.3 | 起(迄)頁: | 383-390 | 來源出版物: | CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 摘要: | Decoy receptor 3 (DcR3/TR6) is a decoy receptor for the Fas ligand (FasL) and can inhibit FasL-induced apoptosis. It has been reported recently that DcR3 can induce T cell activation via co-stimulation of T cells, suggesting that DcR3 may be involved in the pathophysiology of autoimmune diseases. This study aims to analyse the serum DcR3 in patients with systemic lupus erythematosus (SLE) and to investigate the role of DcR3 in the pathogenesis of SLE. Significantly elevated serum DcR3 was observed in SLE patients, and the mean serum DcR3 level was significantly higher for those with active disease [SLE disease activity index (SLEDAI) >= 10] compared with that in patients with inactive disease (SLEDAI < 10). In addition to reducing activation-induced cell death in activated T cells via neutralization of the FasL, soluble DcR3-Fc enhanced T cell proliferation and increased interleukin-2 and interferon- gamma production via co-stimulation of T cells. Moreover, enhanced T cell reactivity to DcR3-induced co-stimulation was demonstrated in lymphocytes from patients with SLE, suggesting the elevated serum DcR3 may associate with enhanced T cell activation in vivo. These findings are the first to demonstrate that serum DcR3 concentrations are increased in SLE patients, and this may imply a possible role of DcR3 in the pathogenesis of SLE via enhanced T cell hyperreactivity and reduced apoptosis in activated T cells. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/174700 |
顯示於: | 醫學檢驗暨生物技術學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。